Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

LifeMap Sciences releases LifeMap Discovery Version 1.2 with extensive stem cell therapy data

LifeMap Sciences : 29 July, 2013  (Company News)
LifeMap Sciences is releasing LifeMap Discovery version 1.2 which is a state-of-the-art roadmap of embryonic development and stem cell biology.


The product integrates embryonic development and stem cell biology, molecular, cellular, anatomical, and disease-related information, and provides data-mining capabilities and bioinformatics applications. As such, it is a powerful tool for research and discovery in multiple disciplines, including stem cell biology, developmental biology and disease mechanisms and etiology.



LifeMap Discovery is a key component in LifeMap's integrated database suite, a discovery platform for biomedical and stem cell research, which also includes GeneCards, the leading human gene database, and MalaCards, the human disease database.



LifeMap Discovery version 1.2 new features and information include the following:




  • Extensive, detailed searchable information on more than 250 stem cell-based therapeutic approaches in research, preclinical, clinical stages, as well as marketed products. For most, we include information describing the cells used and relevant molecular data, delivery, formulation, dosing regimen and mechanism of action. Access to the complete data is available via a LifeMap Discovery Premium subscription.


  • Additional high-throughput gene expression links to MGI, GENSAT and Hudsen - complementing already existing information from Euroexpress, GUDMAP, Human Protein Atlas, Homer, Tiger, Barcode and experiments extracted from the literature and GEO, and establishes LifeMap Discovery as the leading gene expression source for embryonic development, mature cells and tissues. High throughput data is now provided by highlighting the top differentially expressed 100 genes linked to in vivo or in vitro cells based on a differentiated comparison of sample groups, with complete datasets available to researchers on request (see http://discovery.lifemapsc.com/gene-expression-signals/high-throughput). Gene expression search capabilities have been updated through the Gene Search functionality to allow easy access http://discovery.lifemapsc.com/gene-expression-signals/gene-search).




  • New embryonic development data - including the development of the dermis and updated information about early ectoderm and smooth muscle lineages.


  • Enhanced differentiation protocols - additional coverage for popular differentiation protocols including short descriptions and references.





"LifeMap Discovery version 1.2 provides enhanced features related to stem cell therapeutic development," said Ronit Shtrichman, PhD, MBA, Vice President of Biology at LifeMap Sciences. "This version includes substantially upgraded information about stem cells with potential therapeutic applications and stem cell differentiation protocols. It also enables researchers to identify genes specifically expressed during embryonic development and stem cells differentiation, providing the means to generate desired cell types for therapeutic applications."



"The extensive coverage of the stem cell therapy pipeline and high throughput gene expression data are significant steps forward in developing our premium model, and are of significant interest to companies developing cell-based therapies. Coupled with the commercial offering of recombinant proteins and PureStem progenitors, it is an important milestone for commercialization of the LifeMap Discovery platform," said Yaron Guan-Golan, Head of Marketing at LifeMap Sciences.


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo